Adverum Biotechnologies Announces 3-Year Efficacy and

- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of...

Related Keywords

United Kingdom ,California ,United States ,San Francisco ,American ,Carl Regillo ,Laurent Fischer ,Carld Regillo ,Adverum Biotechnologies Inc ,Exchange Commission ,Clinical Program Milestones ,Healthcare Products Regulatory Agency ,Retina Service At Wills Eye Hospital ,Drug Administration ,American Academy Of Ophthalmology ,European Medicines Agency ,Nasdaq ,Retina Subspecialty Day ,American Academy ,Extension Data ,Gene Therapy ,Preliminary Data ,Year Results From ,Protein Data Highlights ,Baseline Characteristics ,Clinical Program ,Program Milestones ,Retina Service ,Wills Eye Hospital ,Fast Track ,Innovation Passport ,Private Securities Litigation Reform Act ,Quarterly Report ,Nasdaq Advm ,Adverum Biotechnologies ,Nc ,Wet Macular Degeneration ,